1. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society
- Author
-
Varaha S Tammisetti, Peter-Paul Willemse, Daniel Rukstalis, Veeru Kasivisvanathan, Xavier Cathelineau, Yoh Matsuoka, Willemien Van Den Bos, Giorgio Gandaglia, Soroush Rais-Bahrami, Takumi Shiraishi, Massimo Valerio, Ardeshir R. Rastinehad, Cary N. Robertson, Herbert Lepor, Rajan T Gupta, Juan Gomez Rivas, Toshitaka Shin, Ariel Schulman, Yann Barbe, A.L. Abreu, Marco Moschini, Arvin K. George, Marco Oderda, Armando Stabile, Amir H. Lebastchi, Nathan Lawrentschuk, Daniel Margolis, Georg Salomon, M.P. Laguna, Wei Phin Tan, Jean J.M.C.H. de la Rosette, Derek Lomas, Christian P Pavlovich, Hazem Orabi, Bernard Malavaud, Abhinav Sidana, Osamu Ukimura, Sherif Mehralivand, Justin Gregg, Fernando Bianco, Thomas J. Polascik, Jochen Walz, Giancarlo Marra, Petr Macek, Rafael Sanchez-Salas, Sunao Shoji, Mesut Remzi, A. Villers, Radiology and Nuclear Medicine, APH - Personalized Medicine, Marra, Giancarlo, Laguna, Maria Pilar, Walz, Jochen, Pavlovich, Christian P, Bianco, Fernando, Gregg, Justin, Lebastchi, Amir H, Lepor, Herbert, Macek, Petr, Rais-Bahrami, Soroush, Robertson, Cary, Rukstalis, Daniel, Salomon, Georg, Ukimura, Osamu, Abreu, Andre L, Barbe, Yann, Cathelineau, Xavier, Gandaglia, Giorgio, George, Arvin K, Rivas, Juan Gomez, T Gupta, Rajan, Lawrentschuk, Nathan, Kasivisvanathan, Veeru, Lomas, Derek, Malavaud, Bernard, Margolis, Daniel, Matsuoka, Yoh, Mehralivand, Sherif, Moschini, Marco, Oderda, Marco, Orabi, Hazem, Rastinehad, Ardeshir R, Remzi, Mesut, Schulman, Ariel, Shin, Toshitaka, Shiraishi, Takumi, Sidana, Abhinav, Shoji, Sunao, Stabile, Armando, Valerio, Massimo, Tammisetti, Varaha S, Tan, Wei Phin, Van Den Bos, Willemien, Villers, Arnaud, Willemse, Peter-Paul, de la Rosette, Jean, Polascik, Thoma, Sanchez-Salas, Rafael, and Urology
- Subjects
Male ,medicine.medical_specialty ,Scoring system ,Consensus ,Urology ,MEDLINE ,Context (language use) ,Prostate cancer ,SDG 3 - Good Health and Well-being ,Surveys and Questionnaires ,Delphi technique ,medicine ,Biomarkers, tumor ,Prostatic neoplasms cancer ,Biomarkers ,Delphi Technique ,Humans ,Prostatic Neoplasms ,Medical physics ,computer.programming_language ,Tumor ,business.industry ,Subject (documents) ,medicine.disease ,Molecular biomarkers ,Focal therapy ,Nephrology ,business ,computer ,Delphi - Abstract
Background Focal Therapy (FT) for Prostate Cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localised PCa. Materials and methods A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, i) the current/present role; ii) the potential/future role; iii) the recommended features for future studies. Consensus was defined using a 70% agreement threshold. Results Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (n=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (n=3), a consensus on a partial agreement (n=1), and a consensus on uncertainty (n=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localised PCa. Research efforts in this field should be considered a priority. Conclusions The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.
- Published
- 2022